| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Sarah Kathryn Rouan is Director at VKTX. Sarah Kathryn Rouan's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $115K at current prices.
Our model assigns Sarah Kathryn Rouan a below-average insider score of 49/100, based on 4 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +7.0%.
The VKTX filings lean toward selling, a net 64,760 shares.
Sarah Kathryn Rouan has 12 Form 4 filings on record from July 2019 to January 2026, all as Director at Viking Therapeutics (VKTX), 2019–2026.
The 16 reported transactions were 8 option or other derivative awards, 3 option exercises, 3 open-market sales and 1 stock award, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $30K and 3 sales worth about $2.3M.
The only open-market purchase was 1,240 shares of VKTX at an average $24.15 on March 31, 2025, about $30K. Twelve months later VKTX was up 35%.
The largest open-market sale was 11,000 shares of VKTX at an average $80.89 on October 25, 2024, about $890K. Twelve months later VKTX was down 56%.
All 3 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | VKTX Viking Therapeutics, Inc. | Director | Buy | 1,240 | $24.15 | $29,942.78 | New | +9.7% | +34.7% | |
| Oct 25, 2024 | VKTX Viking Therapeutics, Inc. | Director | Sale+OE10b5-1 | 11,000 | $80.89 | $889,790.00 | - | -55.2% | -55.9% | |
| Feb 8, 2024 | VKTX Viking Therapeutics, Inc. | Director | Sale+OE10b5-1 | 25,000 | $28.05 | $701,250.00 | - | +176.6% | +12.7% | |
| Jan 19, 2024 | VKTX Viking Therapeutics, Inc. | Director | Sale+OE10b5-1 | 30,000 | $23.05 | $691,500.00 | - | +197.1% | +50.0% |